Expanding initial anti-HBV therapy for chronic hepatitis B: Reducing the treatment threshold of alanine aminotransferase
10.3969/j.issn.1001-5256.2023.01.004
- VernacularTitle:扩大慢性乙型肝炎初始治疗：降低ALT治疗阈值
- Author:
Jiayi ZHANG
1
;
Shuyan CHEN
1
;
Hong YOU
1
Author Information
1. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
- Publication Type:Discussions by Experts
- Keywords:
Hepatitis B, Chronic;
Expanding Treatment;
ALT Treatment Threshold
- From:
Journal of Clinical Hepatology
2023;39(1):27-30
- CountryChina
- Language:Chinese
-
Abstract:
In order to achieve the global goal of eliminating viral hepatitis as a public health threat by 2030 proposed by the World Health Organization, it is of great importance to expand the treatment of chronic hepatitis B patients. Recent studies have shown that alanine aminotransferase (ALT) is associated with liver inflammation, fibrosis, hepatocellular carcinoma, and outcome events of liver disease. Besides, as a strategy for expanding antiviral therapy, reducing the treatment threshold of ALT can reduce the occurrence of liver cirrhosis, hepatocellular carcinoma, and liver-related death. In the Expert opinion on expanding antiviral therapy for chronic hepatitis B published in China in 2022, the treatment indication for chronic hepatitis B patients was updated to positive serum HBV DNA and ALT above the treatment threshold (30 U/L for male and 19 U/L for female), with the exclusion of other causes.
